Laurion Capital Management LP bought a new stake in Repligen Co. (NASDAQ:RGEN) during the third quarter, HoldingsChannel reports. The institutional investor bought 88,359 shares of the biotechnology company’s stock, valued at approximately $4,900,000.

A number of other hedge funds have also recently bought and sold shares of RGEN. SG Americas Securities LLC bought a new position in Repligen in the second quarter valued at about $135,000. Seven Eight Capital LP purchased a new stake in Repligen in the third quarter worth about $217,000. Smith Asset Management Group LP increased its position in Repligen by 1,511.8% in the second quarter. Smith Asset Management Group LP now owns 4,658 shares of the biotechnology company’s stock worth $219,000 after buying an additional 4,369 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Repligen in the second quarter worth about $250,000. Finally, Meadow Creek Investment Management LLC increased its position in Repligen by 21.7% in the second quarter. Meadow Creek Investment Management LLC now owns 7,840 shares of the biotechnology company’s stock worth $369,000 after buying an additional 1,400 shares in the last quarter. 94.72% of the stock is currently owned by institutional investors.

Shares of RGEN opened at $61.73 on Friday. The stock has a market capitalization of $2.76 billion, a price-to-earnings ratio of 86.14, a P/E/G ratio of 4.92 and a beta of 0.70. Repligen Co. has a 52 week low of $29.56 and a 52 week high of $70.50.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.02. Repligen had a return on equity of 5.39% and a net margin of 12.61%. The firm had revenue of $49.53 million during the quarter, compared to analysts’ expectations of $46.69 million. During the same quarter last year, the business posted $0.15 earnings per share. The firm’s revenue was up 35.4% on a year-over-year basis. As a group, sell-side analysts expect that Repligen Co. will post 0.73 EPS for the current year.

In related news, CEO Anthony Hunt sold 27,566 shares of the stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $57.71, for a total transaction of $1,590,833.86. Following the completion of the sale, the chief executive officer now owns 255,017 shares in the company, valued at $14,717,031.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jon Snodgres sold 31,753 shares of the stock in a transaction dated Monday, November 26th. The stock was sold at an average price of $63.49, for a total value of $2,015,997.97. Following the sale, the chief financial officer now owns 32,344 shares of the company’s stock, valued at approximately $2,053,520.56. The disclosure for this sale can be found here. Insiders have sold 61,082 shares of company stock valued at $3,722,749 in the last quarter. 1.40% of the stock is currently owned by company insiders.

RGEN has been the subject of a number of analyst reports. ValuEngine upgraded Repligen from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 23rd. HC Wainwright restated a “hold” rating and issued a $60.00 price target on shares of Repligen in a research report on Monday, November 5th. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $62.00 price target for the company in a research report on Thursday, October 4th. BidaskClub cut Repligen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 25th. Finally, JPMorgan Chase & Co. upped their price target on Repligen from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Friday, November 2nd. Four analysts have rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $62.60.

TRADEMARK VIOLATION NOTICE: “Laurion Capital Management LP Invests $4.90 Million in Repligen Co. (RGEN) Stock” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.watchlistnews.com/laurion-capital-management-lp-invests-4-90-million-in-repligen-co-rgen-stock/2667902.html.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Further Reading: Why is the conference call important?

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.